2359 GMT - Ansell's first-half result may give investors the mistaken impression that it is a growth stock, Morgans analyst Derek Jellinek says. He acknowledges that the protective garment manufacturer's performance was stronger than he had anticipated, but tells clients in a note that it was largely driven by acquisition gains, cost reductions, and one-off items. Customers have now finished restocking after running down inventory built up during the Covid-19 pandemic, he says. This spells an end to what he calls "easy gains" by Ansell's healthcare unit. With tariffs now a factor and potential of sales leakage from a change in processes, Jellinek is cautious. Morgans raises its target price by 23% to A$33.38 but keeps a hold rating on the stock, which is down 2.75% at A$36.73. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
February 10, 2025 18:59 ET (23:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。